ArticleInternational journal of molecular sciences2025
Computational Profiling of Monoterpenoid Phytochemicals: Insights for Medicinal Chemistry and Drug Design Strategies.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disrupting virulence: in silico discovery of MexL inhibitors to block pyocyanin biosynthesis in Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- L-Type Voltage-Gated CaMedical sciences (Basel, Switzerland) · 2026Article
- Anxiolytic-Like Effect ofACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoterpenoids are a structurally diverse class of natural products with a long-standing history of therapeutic use. Despite their promising bioactivities, their clinical development has been limited by dose-dependent toxicities, poor pharmacokinetics, and suboptimal drug-like properties. In this work, a comprehensive in silico pipeline was employed to evaluate 1175 monoterpenoid compounds retrieved from ChEBI, aiming to identify structurally diverse candidates that possess favorable drug-like characteristics. A total of 54 molecular parameters were calculated using thirteen computational tools, covering physicochemical parameters, ADMET profiles, and toxicological risk assessments. Stepwise filtering was employed to retain only compounds meeting stringent thresholds across multiple domains, followed by chemoinformatic analysis. Structure-activity relationship mapping and target prediction were subsequently conducted to explore mechanistic plausibility. This workflow led to the identification of seven top-performing monoterpenoids that exhibited ideal physicochemical profiles, high gastrointestinal absorption, low predicted toxicity, and full compliance with medicinal chemistry rules. Notably, target prediction revealed a convergence on GPCRs, enzymatic and nuclear receptors, highlighting potential anti-inflammatory and neuromodulatory effects. The identification of conserved pharmacophores across selected scaffolds further reinforces their translational potential. Our results highlight the value of multi-parameter computational triage in natural product drug discovery and reveal a subset of overlooked monoterpenoids with promising preclinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.